Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
Archil Jaliashvili, Co-Chief Executive Officer at GeoBio Pharm, Biotech Executive, Strategic Partner of BHOC and Precision Oxygen Therapeutics, shared BHOC – Biological Hemoglobin Oxygen Carrier’s post on LinkedIn:
”The problem is not staying – it is escalating.
Blood and plasma shortages are not just persisting; they are deepening by the day.
And now, new forces are piling on:
- new pandemics,
- wars and conflicts,
- natural disasters,
- logistical breakdowns,
- soaring costs,
- emerging viruses,
- and ever more demanding tests.
- cold chain problem
These are not isolated hurdles – they are a new reality that demands a new understanding.
What is that understanding?
It is this: we must rethink what blood truly is – what we are actually doing, and what we truly need.
Today we state this clearly:
We are not talking about a ‘blood substitute’.
That is the old language.
We are talking about an Precise Oxygenation Therapeutics – to support one of the many critical functions of blood.
BUT – as clear it is main , fundamental function for life, healing, functioning
And here is the key insight:
It is not only about whether blood is available or not.
Even when blood is present – even when supplies are adequate – the blood as an organ still needs support.
We must increase its oxygen-delivery capacity – not just in cases of massive blood loss , hemoglobin level or repeated transfusions, but as a proactive measure to meet the oxygen demands of every patient in crisis.
Because the real battle is not about volume – it is about oxygen.
And that changes everything.”
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”This BBC News article from April 11, 2001, reports that South Africa became the first country in the world to approve a human blood substitute for use in transfusions .
25 years ago, the world already recognized that oxygen delivery does not necessarily have to depend on donor blood.
Dr. Luc Noel was the Coordinator for Blood Transfusion Safety at the WHO in Geneva. He was quoted as saying, “If there is any alternative that is safer than the potential risks of transfusions, then it should be used”
Other posts featuring Archil Jaliashvili on Hemostasis Today.
-
Oct 12, 2026, 17:39Annie Bauzon: Differentiating Direct and Indirect Coombs Tests in Hematology
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026